Research

Blood p-tau217 may estimate cognitive impairment risk up to 10 years ahead

In a Mayo Clinic study, higher p-tau217 levels were associated with greater estimated risk of mild cognitive impairment or dementia over five and 10 years.

Reported by 2 outlets Tuesday, November 17, 2026

Brain scan images on monitors in an MRI control room
Photo: Public domain, U.S. Navy Medicine

A Mayo Clinic study found that blood levels of phosphorylated tau 217 (p-tau217), combined with age, sex and genetic risk, may help estimate a cognitively unimpaired person's likelihood of developing mild cognitive impairment or dementia within five or 10 years. Researchers analyzed 1,644 participants in the Mayo Clinic Study of Aging and 534 in the Alzheimer's Disease Neuroimaging Initiative. Participants were ages 60 to 90.

For example, researchers estimated that a 75-year-old woman who did not carry APOE e4 had a five-year risk of mild cognitive impairment of 5% with a relatively low p-tau217 level and 16% with a higher level. Her estimated 10-year risk rose from 12% to 35%. The researchers said the estimates need further study in more diverse populations and with other p-tau217 tests. Alzheimer's biomarker testing is not currently recommended for people without cognitive symptoms.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.